About
Greenwich Lifesciences
GLSI.US
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc.
Profile
- Company Name
- Greenwich LifeSciences, Inc.
- Market
- NasdaqCM
- Founded
- Industry
- --
- Fiscal Year End
- --
- Website
- greenwichlifesciences.com